RayKnowChina Research Map
Shortlist0

ShanghaiFudan University

Children's Hospital of Fudan University

复旦大学附属儿科医院

Listed for 31 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Children's Hospital of Fudan University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatoblastoma肝母细胞瘤5 papers led
  2. Retinoblastoma视网膜母细胞瘤0 papers led
  3. Chordoma脊索瘤0 papers led
  4. Osteosarcoma骨肉瘤4 papers led
  5. Neuroblastoma神经母细胞瘤11 papers led
  6. Ewing sarcoma尤文肉瘤1 paper led
  7. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
  8. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症0 papers led
  9. Beta thalassaemiaβ 地中海贫血0 papers led1 open trial led
  10. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
  11. Myasthenia gravis重症肌无力1 paper led
  12. Moyamoya disease烟雾病2 papers led
  13. Biliary atresia胆道闭锁21 papers led3 open trials led
  14. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
  15. Takayasu arteritis大动脉炎0 papers led
  16. Spinal muscular atrophy脊髓性肌萎缩症3 papers led
  17. Fabry disease法布雷病1 paper led1 open trial led
  18. Pompe disease庞贝病0 papers led
  19. Duchenne muscular dystrophy杜氏肌营养不良2 papers led
  20. Behçet disease白塞病1 paper led
  21. Alport syndromeAlport 综合征0 papers led
  22. IgA nephropathyIgA 肾病2 papers led
  23. Gaucher disease戈谢病1 paper led
  24. Osteogenesis imperfecta成骨不全症1 paper led
  25. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  26. Congenital diaphragmatic hernia先天性膈疝0 papers led
  27. Hirschsprung disease先天性巨结肠4 papers led
  28. Inherited epidermolysis bullosa遗传性大疱性表皮松解症2 papers led
  29. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led
  30. Majeed syndromeMajeed 综合征1 paper led
  31. NGLY1 deficiencyNGLY1 缺乏症0 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Gastrointestinal stromal tumour, Multiple myeloma, Aplastic anaemia, Haemophilia A, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Wilson disease, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Niemann–Pick disease type C, Primary biliary cholangitis, Hereditary angioedema, Leber hereditary optic neuropathy, ISG15 deficiency.

Cancer

Hepatoblastoma

肝母细胞瘤

Led 5 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 3.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 1120242025: 222025

8 hospitals in Shanghai for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Over half of these papers are lab or animal studies.

Papers it led5
  1. Single-cell profiles delineate immune cell remodeling and enhanced tumor-fibroblast interaction of hepatoblastoma after chemotherapy.2025Cell reports. Medicine
  2. YAP-activated NAT10 promotes hepatoblastoma progression by activating the pentose phosphate pathway.2025International journal of biological sciences
  3. Nutritional status associated with clinical outcomes in children with solid tumors: A retrospective cohort study from China.2024Cancer medicine
  4. USP7 promotes hepatoblastoma progression through activation of PI3K/AKT signaling pathway.2021Cancer biomarkers : section A of Disease markers
  5. ARID1B/SUB1-activated lncRNA HOXA-AS2 drives the malignant behaviour of hepatoblastoma through regulation of HOXA3.2021Journal of cellular and molecular medicine
Earlier papers (2016–2020)6
  1. Role of the long non‑coding RNA‑Annexin A2 pseudogene 3/Annexin A2 signaling pathway in biliary atresia‑associated hepatic injury.2019International journal of molecular medicine
  2. Expression Profiling Identifies Circular RNA Signature in Hepatoblastoma.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  3. Distinguishing Among Pediatric Hepatoblastomas, Transitional Liver Cell Tumors, and Hepatocellular Carcinomas and Using Appropriate Chemotherapy Regimens.2017Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  4. Circulating D-dimer level correlates with disease characteristics in hepatoblastoma patients.2017Medicine
  5. Long non-coding RNA-CRNDE: a novel regulator of tumor growth and angiogenesis in hepatoblastoma.2017Oncotarget
  6. Targeting long non-coding RNA-TUG1 inhibits tumor growth and angiogenesis in hepatoblastoma.2016Cell death & disease
All its trials on ClinicalTrials.gov, any status1
  1. G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorStatus unknownNCT02933333Study sitePhase 4Start 2016-09

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

11 hospitals in Shanghai for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorStatus unknownNCT02933333Study sitePhase 4Start 2016-09

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

15 hospitals in Shanghai for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Poorly-differentiated chordoma with INI1 loss: a clinicopathologic study].2017Zhonghua bing li xue za zhi = Chinese journal of pathology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 4 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 112025

60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 11 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 1.0%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 5520232024: 2220242025: 222025

34 hospitals in Shanghai for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsPathology / laboratory medicine
Papers it led11
  1. The Psychological Experience of Caregivers of Children With Neuroblastoma Undergoing Naxitamab Treatment: A Qualitative Study in China.2025Child: care, health and development
  2. CAMK2G Promotes Neuronal Differentiation and Inhibits Migration in Neuroblastoma.2025Journal of pediatric surgery
  3. Nutritional status associated with clinical outcomes in children with solid tumors: A retrospective cohort study from China.2024Cancer medicine
  4. Clinical impact and in vitro characterization of ADNP variants in pediatric patients.2024Molecular autism
  5. Discovery, evaluation and mechanism study of WDR5-targeted small molecular inhibitors for neuroblastoma.2023Acta pharmacologica Sinica
  6. Circulating tumor cells in neuroblastoma: Current status and future perspectives.2023Cancer medicine
  7. FAM201A encodes small protein NBASP to inhibit neuroblastoma progression via inactivating MAPK pathway mediated by FABP5.2023Communications biology
  8. Inducible Expression of Amphinase in Neuroblastoma Cells using Cre/LoxP System.2023Journal of pediatric surgery
  9. Incidental Neuroblastoma.2023The New England journal of medicine
  10. Downregulation of MEG3 and upregulation of EZH2 cooperatively promote neuroblastoma progression.2022Journal of cellular and molecular medicine
  11. PHOX2B as a Reliable Marker for Neuroblastoma in Tissue and Cytology Specimens.2021Journal of neuropathology and experimental neurology
Earlier papers (2016–2020)16
  1. Single-Cell Characterization of Malignant Phenotypes and Developmental Trajectories of Adrenal Neuroblastoma.2020Cancer cell
  2. Role of long noncoding RNA in neuroblastoma.2020Discovery medicine
  3. Mass screening for neuroblastoma in infants.2020Discovery medicine
  4. Downregulation of MEG3 promotes neuroblastoma development through FOXO1-mediated autophagy and mTOR-mediated epithelial-mesenchymal transition.2020International journal of biological sciences
  5. Circulating tumor DNA in neuroblastoma.2020Pediatric blood & cancer
  6. TRIM59 knockdown inhibits cell proliferation by down-regulating the Wnt/β-catenin signaling pathway in neuroblastoma.2019Bioscience reports
  7. The association between lncRNA LINC01296 and the clinical characteristics in neuroblastoma.2019Journal of pediatric surgery
  8. Prognostic factor analysis of stage 4S neuroblastoma in infant patients: A single center study.2019Journal of pediatric surgery
  9. Long-term prognosis of low-risk neuroblastoma treated by surgery alone: an experience from a single institution of China.2019World journal of pediatrics : WJP
  10. Circulating tumor cells detection in neuroblastoma patients by EpCAM-independent enrichment and immunostaining-fluorescence in situ hybridization.2018EBioMedicine
  11. Comparison of long-term prognosis of laparoscopic and open adrenalectomy for local adrenal neuroblastoma in children.2018Pediatric surgery international
  12. Downregulation of bone morphogenetic protein receptor 2 promotes the development of neuroblastoma.2017Biochemical and biophysical research communications
  13. Variable MIBG Activity in the Same Renal Cyst.2017Clinical nuclear medicine
  14. Artemether Regulates Chemosensitivity to Doxorubicin via Regulation of B7-H3 in Human Neuroblastoma Cells.2017Medical science monitor : international medical journal of experimental and clinical research
  15. Epidermal growth factor receptor is overexpressed in neuroblastoma tissues and cells.2016Acta biochimica et biophysica Sinica
  16. MEG3, HCN3 and linc01105 influence the proliferation and apoptosis of neuroblastoma cells via the HIF-1α and p53 pathways.2016Scientific reports
All its trials on ClinicalTrials.gov, any status2
  1. Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in ChildrenStatus unknownNCT02919046Study siteN/AStart 2016-09
  2. G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorStatus unknownNCT02933333Study sitePhase 4Start 2016-09

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

15 hospitals in Shanghai for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsPathology / laboratory medicine
Papers it led1
  1. Single-cell transcriptional profiling reveals heterogeneity and developmental trajectories of Ewing sarcoma.2022Journal of cancer research and clinical oncology
Chinese-language papers (not in the count)1
  1. [Interpretation of the soft tissue specific tumors in the 5th WHO classification of pediatric tumors].2025Zhonghua bing li xue za zhi = Chinese journal of pathology

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution

9 hospitals in Shanghai for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06764238

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an

  2. Recruiting
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06882057

    Age 1 year to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  3. Recruiting
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT07152041

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status5
  1. Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaStatus unknownNCT04173988Lead sponsorEarly phase 1Start 2020-01
  2. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Study sitePhase 2/Phase 3Start 2025-01
  3. Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Study sitePhase 3Start 2025-03
  4. Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolRecruitingNCT06882057Study sitePhase 2/Phase 3Start 2025-03
  5. A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma SubjectsStatus unknownNCT03265106Study sitePhase 1/Phase 2Start 2016-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led no English-language PubMed papers on haemophagocytic lymphohistiocytosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

5 hospitals in Shanghai for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07208058

    Age 16 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Shanghai for beta thalassaemia157 hospitals in China for beta thalassaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Long-term Follow-up Study in Participants Who Received CS-101
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT06479616

    Age 3 years to 17 years (registered criteria)

    Led by Children's Hospital of Fudan UniversityShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status4
  1. A Long-term Follow-up Study in Participants Who Received CS-101RecruitingNCT06479616Lead sponsorN/AStart 2024-06
  2. Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia MajorCompletedNCT06065189Lead sponsorEarly phase 1Start 2023-11
  3. A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia MajorNot yet recruitingNCT07489196Study sitePhase 2Start 2026-04
  4. A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia MajorCompletedNCT06291961Study sitePhase 1Start 2024-04

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Shanghai for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 1 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

7 hospitals in Shanghai for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT04535843

    Age 0 years to 90 years (registered criteria)

    Led by Huashan Hospital; 1 listed hospital as study siteShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStandard immunotherapyPregnancy, children, older adults
Departments in papersNeurology
Papers it led1
  1. Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis.2023Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
All its trials on ClinicalTrials.gov, any status2
  1. Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in ChinaRecruitingNCT04535843Study siteStart 2024-02
  2. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisTerminatedNCT04963270Study sitePhase 3Start 2021-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

4 hospitals in Shanghai for moyamoya disease47 hospitals in China for moyamoya disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07894107

    Age 12 years to 70 years (registered criteria)

    Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRevascularisation surgeryImaging & blood flowChildren

Run the PubMed searchClinicalTrials.gov

Other diseases

Biliary atresia

胆道闭锁

Led 21 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 9.8%.

Papers led
21
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 4420232024: 4420242025: 662025

3 hospitals in Shanghai for biliary atresia28 hospitals in China for biliary atresia

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
    Phase
    Not given
    Started
    2023-10
    Registry
    NCT05848310

    Age not stated (registered criteria)

    Led by Children's Hospital of Fudan UniversityShanghai

  2. Recruiting
    Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy
    Phase
    N/A
    Started
    2023-07
    Registry
    NCT05925309

    Age 14 days to 90 days (registered criteria)

    Led by Children's Hospital of Fudan UniversityShanghai

  3. Recruiting
    High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia
    Phase
    Not given
    Started
    2021-10
    Registry
    NCT05072626

    Age Not stated to 3 months (registered criteria)

    Led by Children's Hospital of Fudan UniversityShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDisease mechanismsScreening & diagnosisLong-term outcomes
Departments in papersPediatricsSurgery (general/hepatobiliary/pancreatic)
Papers it led21
  1. RNA m6A methylation regulates CDH6 to promote epithelial-to-mesenchymal transition in cholangiocytes of biliary atresia.2026Journal of pediatric surgery
  2. Potential therapeutic effect of dimethyl fumarate on Treg/Th17 cell imbalance in biliary atresia.2025Clinical immunology (Orlando, Fla.)
  3. Single-cell transcription reveals hepatocyte-to-cholangiocyte reprogramming and biliary gene profile in biliary atresia.2025Hepatology communicationsFree full text
  4. Establishment of Biliary Atresia Prognostic Classification System via Survival-Based Forward Clustering - A New Biliary Atresia Classification.2025Indian journal of pediatrics
  5. Serum FGF19 combined with GGT and other biomarkers predicted native liver survival following Kasai portoenterostomy in early biliary atresia.2025Journal of gastroenterology
  6. LncRNA MEG9 Promotes Inflammation and Liver Fibrosis Through S100A9 in Biliary Atresia.2025Journal of pediatric surgery
  7. Development and validation of a minimally invasive diagnostic model for biliary atresia using artificial intelligence.2025World journal of pediatrics : WJPFree full text
  8. Incidence and outcome of biliary atresia in Shanghai, China from 2015 to 2016: a cohort study.2024BMJ paediatrics openFree full text
  9. NLRP3 inflammasome activation promotes liver inflammation and fibrosis in experimental biliary atresia.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  10. Clinical Characteristics and Prognosis of Biliary Atresia with Low Serum Matrix Metalloproteinase-7 Levels.2024Journal of pediatric surgery
  11. Serum matrix metalloproteinase-7 for discriminating biliary atresia: a diagnostic accuracy and validation study.2024Journal of translational medicineFree full text
  12. Psychological Journey and Coping Styles of Parents of Infants With Biliary Atresia: A Single-Center Qualitative Study.2023Advances in neonatal care : official journal of the National Association of Neonatal NursesFree full text
  13. Effect of Adjuvant Steroid Therapy in Type 3 Biliary Atresia: A Single-Center, Open-Label, Randomized Controlled Trial.2023Annals of surgeryRCT
  14. Integrative analysis implicates the significance of m6A in the liver fibrosis of biliary atresia by regulating THY1.2023Hepatology communicationsFree full text
  15. Biliatresone: progress in biliary atresia study.2023World journal of pediatrics : WJPFree full text
  16. Single-cell and spatial transcriptomics reveal the fibrosis-related immune landscape of biliary atresia.2022Clinical and translational medicineFree full text
  17. Gamma-glutamyl transpeptidase has different efficacy on biliary atresia diagnosis in different hospital patient groups: an application of machine learning approach.2022Pediatric surgery international
  18. Characteristics of SOX9-positive progenitor-like cells during cholestatic liver regeneration in biliary atresia.2022Stem cell research & therapyFree full text
  19. Epidemiological characteristics and risk factors of biliary atresia: a case-control study.2021BMJ openFree full text
  20. Preventive effect of prophylactic intravenous antibiotics against cholangitis in biliary atresia: a randomized controlled trial.2021Pediatric surgery internationalRCT
  21. Effect and mechanism of vitamin D activation disorder on liver fibrosis in biliary atresia.2021Scientific reportsFree full text
All its trials on ClinicalTrials.gov, any status8
  1. Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai PortoenterostomyRecruitingNCT05925309Lead sponsorN/AStart 2023-07
  2. Preoperative Serum FGF19 in the Prognosis of Biliary AtresiaRecruitingNCT05848310Lead sponsorStart 2023-10
  3. High Medium-chain Triglyceride Nutritional Support in Infants With Biliary AtresiaRecruitingNCT05072626Lead sponsorStart 2021-10
  4. A Peer Support Network System Construction for the Primary Caregivers of Children With Biliary AtresiaCompletedNCT05503394Lead sponsorN/AStart 2022-08
  5. Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomyTerminatedNCT06121375Study sitePhase 2/Phase 3Start 2024-09
  6. An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary AtresiaActive, not recruitingNCT05426733Study sitePhase 3Start 2022-07
  7. Evaluation of Maralixibat in Biliary Atresia Response Post-KasaiCompletedNCT04524390Study sitePhase 2Start 2021-07
  8. Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)CompletedNCT04336722Study sitePhase 3Start 2020-07
More papers found outside PubMed (not counted)1
  1. Protocol for a diagnostic accuracy study to develop diagnosis algorithm for biliary atresia using MMP-7 (DIABA-7 study): a study recruiting from Chinese Biliary Atresia Collaborative Network2021BMJ Openarticle

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

9 hospitals in Shanghai for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Shanghai for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led 3 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 5.5%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 112025

6 hospitals in Shanghai for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07221669

    Age 0 days to 42 days (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Zhengzhou

  2. Recruiting
    A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Registry
    NCT07554924

    Age Not stated to 180 days (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurologyPediatrics
Papers it led3
  1. Administration practices of and adherence to nusinersen in children with spinal muscular atrophy: a multicenter disease registry study in China.2025BMC pediatrics
  2. Nusinersen effectiveness and safety in pediatric patients with 5q-spinal muscular atrophy: a multi-center disease registry in China.2024Journal of neurology
  3. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.2021The New England journal of medicine
All its trials on ClinicalTrials.gov, any status9
  1. A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)RecruitingNCT07221669Study sitePhase 3Start 2026-04
  2. A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type IRecruitingNCT07554924Study sitePhase 1/Phase 2Start 2026-07
  3. A Long-term Follow-up Study Evaluating Intravenous Injection of EXG001-307 in Patients With Type 1 SMAEnrolling by invitationNCT06588803Study siteStart 2025-03
  4. Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular AtrophyEnrolling by invitationNCT06888661Study siteEarly phase 1Start 2025-03
  5. Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1Status unknownNCT05614531Study sitePhase 1/Phase 2Start 2023-02
  6. A Clinical Study Evaluating the Safety and Efficacy of SKG0201 Injection in Patients With Spinal Muscular Atrophy Type 1Active, not recruitingNCT06191354Study siteN/AStart 2023-06
  7. Pediatric Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05042921Study siteStart 2021-11
  8. A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) ParticipantsCompletedNCT02908685Study sitePhase 2Start 2016-10
  9. Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular AtrophyCompletedNCT02913482Study sitePhase 2Start 2016-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

6 hospitals in Shanghai for Fabry disease85 hospitals in China for Fabry disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Evaluation of the Safety, Tolerability and Efficacy of a Gene Therapy Drug for the Treatment of Pediatric Fabry Disease
    Phase
    Early phase 1
    Started
    2024-02
    Registry
    NCT06207552

    Age 7 years to 18 years (registered criteria)

    Led by Children's Hospital of Fudan UniversityShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrology
Papers it led1
  1. Multidisciplinary approach to screening and management of children with Fabry disease: practice at a Tertiary Children's Hospital in China.2021Orphanet journal of rare diseases
Chinese-language papers (not in the count)1
  1. [Recent advances in the diagnosis and treatment of Fabry disease].2023Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status2
  1. Evaluation of the Safety, Tolerability and Efficacy of a Gene Therapy Drug for the Treatment of Pediatric Fabry DiseaseRecruitingNCT06207552Lead sponsorEarly phase 1Start 2024-02
  2. Fabry Aim Children Early (ACE) ProjectWithdrawnNCT04965467Lead sponsorStart 2021-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led no English-language PubMed papers on Pompe disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Shanghai for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 2 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

12 hospitals in Shanghai for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

15 hospitals in Shanghai for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Shanghai for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Chinese-language papers (not in the count)1
  1. [Short-term efficacy of dapagliflozin in children with hereditary proteinuric kidney disease].2023Zhonghua er ke za zhi = Chinese journal of pediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

26 hospitals in Shanghai for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led 1 of the 30 English-language PubMed papers on Gaucher disease with an author in mainland China, 2021–2025: 3.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

4 hospitals in Shanghai for Gaucher disease41 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Shanghai for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led1
  1. Clinical severity prediction in children with osteogenesis imperfecta caused by COL1A1/2 defects.2022Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

13 hospitals in Shanghai for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led1
  1. Biallelic loss-of-function ZFYVE19 mutations are associated with congenital hepatic fibrosis, sclerosing cholangiopathy and high-GGT cholestasis.2021Journal of medical genetics
Chinese-language papers (not in the count)1
  1. [An updated advance of autoimmune hepatitis in children].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led no English-language PubMed papers on congenital diaphragmatic hernia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Shanghai for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 4 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 2.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 0020242025: 002025

5 hospitals in Shanghai for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 2 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 3.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

7 hospitals in Shanghai for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

9 hospitals in Shanghai for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Chinese-language papers (not in the count)1
  1. [Interpretation on genetic tumour syndromes in the 5th WHO classification of paediatric tumours: part Ⅱ].2024Zhonghua bing li xue za zhi = Chinese journal of pathology

Run the PubMed searchClinicalTrials.gov

Other diseases

Majeed syndrome

Majeed 综合征

Led 1 of the 3 English-language PubMed papers on Majeed syndrome with an author in mainland China, 2021–2025: 33.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Shanghai for Majeed syndrome7 hospitals in China for Majeed syndrome

No open trial on Majeed syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

NGLY1 deficiency

NGLY1 缺乏症

Led no English-language PubMed papers on NGLY1 deficiency in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shanghai for NGLY1 deficiency2 hospitals in China for NGLY1 deficiency

No open trial on NGLY1 deficiency lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

复旦大学附属儿科医院

Children's Hospital of Fudan University

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Institutes of Biomedical Sciences and Children's Hospital; Children's Hospital; Children's Hospital of Fudan University (Xiamen Branch); Children's Hospital of Fudan University at Xiamen; CHFU; Fudan Children's Hospital

Suggest a correctionDownload the data